Tuesday, April 14, 2020 4:02:19 PM
Recent SONN News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/07/2024 05:15:13 AM
- Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 11/06/2024 06:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/06/2024 02:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 01:48:59 PM
- Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates • GlobeNewswire Inc. • 11/06/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/04/2024 02:01:21 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/28/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 12:50:32 PM
- Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq • GlobeNewswire Inc. • 10/17/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 12:56:20 PM
- Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India • GlobeNewswire Inc. • 10/09/2024 12:45:00 PM
- Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs • GlobeNewswire Inc. • 10/04/2024 12:30:00 PM
- Sonnet BioTherapeutics Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:30:28 PM
- Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 09/25/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:36:17 PM
- Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors • GlobeNewswire Inc. • 09/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:08:40 PM
- Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 09/04/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:30:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/19/2024 09:27:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 12:50:25 PM
- Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 08/19/2024 12:45:00 PM
FEATURED SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • Nov 7, 2024 7:00 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM